What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cancer
Marc Lémann spends much of his time researching Internal medicine, Surgery, Crohn's disease, Inflammatory bowel disease and Gastroenterology.
His is involved in several facets of Internal medicine study, as is seen by his studies on Infliximab, Ulcerative colitis, Randomized controlled trial, Risk factor and Mesalazine.
His Surgery study also includes fields such as
- Azathioprine, which have a strong connection to Mercaptopurine,
- Colectomy, which have a strong connection to Complication.
The Crohn's disease study combines topics in areas such as Predictive value of tests, Severity of illness, Maintenance therapy and Antimetabolite.
His Inflammatory bowel disease study contributes to a more complete understanding of Disease.
His Gastroenterology study combines topics in areas such as Colonoscopy, Threshold of pain and Distension.
His most cited work include:
- Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci (2035 citations)
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management (1239 citations)
- Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. (1061 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Gastroenterology, Crohn's disease, Surgery and Inflammatory bowel disease.
Many of his research projects under Internal medicine are closely connected to In patient with In patient, tying the diverse disciplines of science together.
His Gastroenterology study combines topics from a wide range of disciplines, such as Retrospective cohort study, Complication, Refractory and Chemotherapy.
His research in Crohn's disease intersects with topics in Randomized controlled trial, Certolizumab pegol and Immunology.
His studies in Surgery integrate themes in fields like Adverse effect, Clinical trial and Cohort study.
His study looks at the intersection of Inflammatory bowel disease and topics like Cohort with Thiopurine methyltransferase.
He most often published in these fields:
- Internal medicine (59.06%)
- Gastroenterology (41.34%)
- Crohn's disease (30.31%)
What were the highlights of his more recent work (between 2008-2014)?
- Internal medicine (59.06%)
- Crohn's disease (30.31%)
- Gastroenterology (41.34%)
In recent papers he was focusing on the following fields of study:
Marc Lémann mainly investigates Internal medicine, Crohn's disease, Gastroenterology, Inflammatory bowel disease and Surgery.
His work on Infliximab, Certolizumab pegol, Cohort and Azathioprine is typically connected to In patient as part of general Internal medicine study, connecting several disciplines of science.
His Crohn's disease research integrates issues from Tumor necrosis factor alpha, Immunology, Clinical trial and Mesalazine.
The various areas that Marc Lémann examines in his Gastroenterology study include Enterocutaneous fistula, Refractory, Retrospective cohort study and Graft-versus-host disease.
His Inflammatory bowel disease study integrates concerns from other disciplines, such as Pregnancy, Genetics and Ulcerative colitis.
His Surgery research is multidisciplinary, incorporating perspectives in Hazard ratio, Cohort study and Lymphoma.
Between 2008 and 2014, his most popular works were:
- Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci (2035 citations)
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management (1239 citations)
- Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. (1061 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Disease
Marc Lémann mainly focuses on Internal medicine, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis and Surgery.
His research is interdisciplinary, bridging the disciplines of Gastroenterology and Internal medicine.
His study in Genetics extends to Inflammatory bowel disease with its themes.
In his study, Severity of illness, Scoring severity and Visual analogue scale is inextricably linked to Clinical trial, which falls within the broad field of Crohn's disease.
His studies deal with areas such as Thiopurine methyltransferase, Cohort study and Cohort as well as Surgery.
He interconnects Gastrointestinal agent, Adalimumab and Maintenance therapy in the investigation of issues within Infliximab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
